Elsevier created a COVID-19 resource centre in January 2020, offering free English and Mandarin information on the virus. The centre is hosted on Elsevier Connect, and the company grants permission to make all related research freely available in PubMed Central and other repositories for research use. The Sinus and Allergy Health Partnership developed guidelines for acute bacterial rhinosinusitis (ABRS) in 2000, updated to include recent information on management, antimicrobial susceptibility, and treatment options. ABRS is often preceded by a viral upper respiratory infection, and diagnosis is based on symptoms not improving after 10 days or worsening after 5-7 days. Physical exams and imaging are not always necessary. Common bacteria causing ABRS include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Resistance to antibiotics is a growing concern, particularly with S. pneumoniae. Antibiotic treatment guidelines for ABRS are divided into two categories: mild symptoms with no recent antibiotic use and mild or moderate disease with recent antibiotic use. The primary goal of antibiotics is to eliminate bacteria, reducing symptoms, preventing complications, and avoiding chronic disease. The effectiveness of antibiotics varies, with fluoroquinolones, amoxicillin/clavulanate, and others showing higher efficacy. For adults, recommended initial treatments include amoxicillin/clavulanate, amoxicillin, cefpodoxime, and others. For children, high-dose amoxicillin/clavulanate is recommended. If symptoms do not improve after 72 hours, treatment should be reassessed. The guidelines emphasize the importance of distinguishing between viral and bacterial infections, avoiding unnecessary antibiotic use, and reducing resistance. They also highlight the need for further research to improve diagnosis and treatment strategies for ABRS.Elsevier created a COVID-19 resource centre in January 2020, offering free English and Mandarin information on the virus. The centre is hosted on Elsevier Connect, and the company grants permission to make all related research freely available in PubMed Central and other repositories for research use. The Sinus and Allergy Health Partnership developed guidelines for acute bacterial rhinosinusitis (ABRS) in 2000, updated to include recent information on management, antimicrobial susceptibility, and treatment options. ABRS is often preceded by a viral upper respiratory infection, and diagnosis is based on symptoms not improving after 10 days or worsening after 5-7 days. Physical exams and imaging are not always necessary. Common bacteria causing ABRS include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Resistance to antibiotics is a growing concern, particularly with S. pneumoniae. Antibiotic treatment guidelines for ABRS are divided into two categories: mild symptoms with no recent antibiotic use and mild or moderate disease with recent antibiotic use. The primary goal of antibiotics is to eliminate bacteria, reducing symptoms, preventing complications, and avoiding chronic disease. The effectiveness of antibiotics varies, with fluoroquinolones, amoxicillin/clavulanate, and others showing higher efficacy. For adults, recommended initial treatments include amoxicillin/clavulanate, amoxicillin, cefpodoxime, and others. For children, high-dose amoxicillin/clavulanate is recommended. If symptoms do not improve after 72 hours, treatment should be reassessed. The guidelines emphasize the importance of distinguishing between viral and bacterial infections, avoiding unnecessary antibiotic use, and reducing resistance. They also highlight the need for further research to improve diagnosis and treatment strategies for ABRS.